Joaquin Seras Franzoso I am researcher and PI at the Drug Delivery & Targeting Group belonging to the "Advanced Therapies and Advanced Interventions, Nanomedicine, Transplant & Donation - AVANT " eCORE at Vall d'Hebron Institute of Research (VHIR). I combine this main activity with acting as associate lecturer at the Autonomous University of Barcelona (UAB). Institutions of which they are part Main researcher Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) Vall Hebron Institut de Recerca LinkedIn Twitter Orcid Joaquin Seras Franzoso LinkedIn Twitter Orcid Institutions of which they are part Main researcher Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) Vall Hebron Institut de Recerca I am researcher and PI at the Drug Delivery & Targeting Group belonging to the "Advanced Therapies and Advanced Interventions, Nanomedicine, Transplant & Donation - AVANT " eCORE at Vall d'Hebron Institute of Research (VHIR). I combine this main activity with acting as associate lecturer at the Autonomous University of Barcelona (UAB).
I performed my PhD at the Autonomous University of Barcelona (UAB, 2012). There, I focused on the development of first-in-class biomedical uses for bacterial Inclusion Bodies (IBs). IBs are recombinant protein deposits, between the nano- and micro scale, historically discarded as waste by products of protein production. My research studied the IB-exerted stimuli on mammalian cell interfaces when producing complex nanotopographies for tissue engineering. After my PhD I devoted myself to expand the catalogue of biomedical uses for IBs, as high added value biomaterials. I engineered IBs to be used as depots for the slow release of therapeutic proteins, polyvalent coatings and immunomodulatory particles. I moved to Vall d'Hebron Research Institute (VHIR) in 2015 awarded with an AECC post-doctoral fellowship. Here, I have continued my work in the nano-sphere. Particularly, I have participated in the development of Polymeric Micelles (PM) for the PM-mediated intracellular delivery of therapeutic antibodies, targeting cancer stem cell intrinsic drug resistance. In parallel, I started to explore the potential of extracellular vesicles (EVs). First, as central mediators of intercellular communication with roles in cancer cell plasticity regulation and premetastatic niche conditioning. Secondly, exploiting EVs capacity as protein delivery systems. In this regard, I focused on the generation of protein therapeutics loaded in vivo into EVs. This approach combines protein production and NP functionalization in a single step with intended applications in rare diseases and cancer therapy. I have participated in >20 competitive projects with an accumulated funding of > 3 Milion euros (PI of two). This activity rendered >50 articles (hi=25) in international journals and >60 contributions to congresses. Complementing this activity I engaged teaching undergraduates (2010-2012 & 2021 - , AQU Lecturer accreditation) at UAB and mentoring master and PhD students.
Projects Tumor-derived extracellular vesicles as protein delivery carriers to modulate cancer stem cell dynamic phenotype and metastatic niche-conditioning through cellular inter-communication. IP: - Collaborators: Joaquin Seras Franzoso, Simon Schwartz Navarro Funding agency: Instituto de Salud Carlos III Funding: 135520 Reference: PI20/01474 Duration: 01/01/2021 - 05/04/2021 Desenvolupament de noves nanopartícules funcionals dirigides al nòdul limfàtic per a l'eliminació del reservori latent de VIH IP: María José Buzón Gómez Collaborators: Desenvolupament de noves nanopartícules funcionals dirigides al nòdul limfàtic per a l'eliminació del reservori latent de VIH, Juan Lorente Guerrero, Laura García Latorre, Jordi Temprana Salvador, Joaquin Seras Franzoso, Simon Schwartz Navarro, Jordi Navarro Mercadé, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Judit Grau Exposito, Meritxell Genesca Ferrer, Diana Fernandes de Rafael Funding agency: Fundació La Marató de TV3 Funding: 199998.75 Reference: 20180510 Duration: 10/05/2019 - 31/12/2022 Evolvable platform for designing cancer treatment strategies using nanoparticles (EVO-NANO) IP: - Collaborators: Joaquin Seras Franzoso, Simon Schwartz Navarro, Sandra Mancilla Zamora, Evolvable platform for designing cancer treatment strategies using nanoparticles (EVO-NANO), Belen Garcia Prats Funding agency: EUROPEAN COMMISSION Funding: 568847.5 Reference: EVO-NANO_H2020FETOPEN2017 Duration: 01/10/2018 - 31/03/2022 Terapia combinada mediante nuevos nanoconjugados terapéuticos contra Células Madre Tumorales en tumores de mamas triple negativos IP: Simon Schwartz Navarro Collaborators: Laura García Latorre, Joaquin Seras Franzoso, Diana Fernandes de Rafael Funding agency: Instituto de Salud Carlos III Funding: 123420 Reference: PI17/02242 Duration: 01/01/2018 - 31/12/2020 Pagination First page « Previous page ‹ Page 1 Page 2 Current page 3 Page 4 Next page › Last page »
